Search Result

Results for "

HBsAg

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) FXR (1) HBV (36) HIV (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (1) Infection (36) Inflammation/Immunology (4) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155547

HBV-IN-34	HBV	Infection
HBV-IN-34 (compound 17i) is a potent HBsAg production inhibitor. HBV-IN-34 exhibits excellent in vitro anti-HBV potency, with an EC₅₀ of 0.018 μM and 0.044 μM for HBV DNA and HBsAg, respectively .

HY-145055

HBV-IN-11	HBV	Infection
HBV-IN-11 is a potent HBsAg secretion inhibitor with an EC₅₀ of 0.46 µM (From patent WO2018085619A1, example 28) .

HY-N3093

Periglaucine B (+)-Periglaucine B	HBV	Infection
Periglaucine B ((+)-Periglaucine B) is an alkaloid and an HBsAg inhibitor. Periglaucine B can be isolated from Pericampylus glaucus. Periglaucine B inhibits the secretion of hepatitis B virus (HBV) surface antigen (HBsAg) in Hep G2.2.15 cells with an IC₅₀ of 0.47 mM .

HY-P4043

Hepatitis b virus pre-s region (120-145)	HBV	Infection Inflammation/Immunology
Hepatitis b virus pre-s region (120-145) is a preS2 peptide that inhibits the binding of single-chain Fv fragment (scFv) or IgG to r-HBsAg .

HY-P99541

Tuvirumab anti-hepatitis B; OST 577; SDZ-OST 577	HBV	Infection
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .

HY-145060

HBV-IN-13	HBV	Infection
HBV-IN-12 is a potent hepatitis B surface antigen *(HBsAg)* inhibitor. From patent WO2021204252A1, compound 1_B .

HY-P4045

HBV Seq2 aa:208-216	HBV	Infection
HBV Seq2 aa:208-216, a HBsAg derived CD8 epitope peptide, is studied as part of Large envelope protein from Hepatitis B virus .

HY-157993

SAG-524	HBV	Infection
SAG-524 is a potent oral small molecule HBV viral replication inhibitor. SAG-524 decreased HBV-DNA and HbsAg levels in supernatant of HepG2.2.15 cells, IC₅₀ 0.92 and 1.4 nM, respectively .

HY-148782

HBV-IN-31	HBV	Infection
HBV-IN-31 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-31 shows anti-HBV activity with an IC₅₀ value of 0.13 µM for HBsAg. HBV-IN-31 inhibits cell growth .

HY-148783

HBV-IN-32	HBV	Infection
HBV-IN-32 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-32 shows anti-HBV activity with an IC₅₀ value of 0.14 µM for HBsAg. HBV-IN-32 inhibits cell growth .

HY-145053

HBV-IN-10	HBV	Infection
HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen *(HBsAg)* inhibitor (0.001 μM< EC₅₀ ≤0.05 μM). From patent WO2021204258A1, compound 6 .

HY-N3094

Periglaucine A	HBV HIV	Infection
Periglaucine A, a hasubanane-type alkaloid, can be isolated from Pericampylus glaucus. Periglaucine A can inhibits HBV surface antigen (HBsAg) secretion in Hep G2.2.15 cells. Periglaucine A also shows anti-HIV-1 activity in C8166 cells (EC₅₀: 204 μM) .

HY-133721

Chamaechromone	HBV	Infection Inflammation/Immunology
Chamaechromone is a biflavonoid ingredient isolated from the roots of Stellera chamaejasme L. (Thymelaeaceae). Chamaechromone possesses anti-hepatitis B virus (HBV) effects against the surface antigen of HBV (HBsAg) secretion and has insecticidal activities .

HY-N2882

Apigenin-4'-α-L-rhamnoside	HBV	Infection
Apigenin-4'-α-L-rhamnoside is a potent inhibitor of HBV. Apigenin-4'-α-L-rhamnoside inhibits the secretory level of HBV surface antigen (HBsAg) in HepG2.2.15 cells .

HY-145053A

(5S,8R)-HBV-IN-10	HBV	Infection
(5S,8R)-HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen *(HBsAg)* inhibitor (0.001 μM< EC₅₀ ≤0.05 μM). From patent WO2021204258A1, compound 6 .

HY-126970

HBF-0259	HBV	Infection
HBF-0259 is a potent and selective inhibitor of hepatitis B virus (HBV) surface antigen (HBsAg) secretion, with an EC₅₀ of 1.5 μM in HepG2.2.15 cells. HBF-0259 has no effect on HBV DNA synthesis .

HY-145059

HBV-IN-12	HBV	Infection
HBV-IN-12 is a potent hepatitis B surface antigen *(HBsAg)* inhibitor (0.001 μM< EC₅₀ ≤0.05 μM). HBV-IN-12 shows anti-HBV DNA activity (0.001 μM＜EC₅₀ ≤0.02 μM). From patent WO2021204252A1, compound 15 .

HY-147863

HBV-IN-24	HBV	Infection Neurological Disease
HBV-IN-24 (compound (2ʹS, 6S)-1a) is a potent HBV inhibitor. HBV-IN-24 exhibits potent inhibition activity against HBV DNA, HBsAg, and HBeAg, with EC₅₀ values of 0.6, 0.6, and 4.6 nM, respectively. HBV-IN-24 shows excellent antiviral activity, could have improved neurotoxicity .

HY-162579

TLR7 agonist 22	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 22 (Compound 11a) emerges as a selective TLR7 agonist with an IC₅₀ value of 25.86 μM. TLR7 agonist 22 inhibits the cellular HBsAg secretion and effectively activates TLR7, thereby inducing the secretion of TLR7-regulated cytokines IL-12, TNF-αand IFN-αin human PBMC cells. TLR7 agonist 22 is a promising for research in the field of developing novel immunomodulatory anti-HBV agents .

HY-123336

Schisantherin C	HBV	Infection
Schisantherin C exhibits anti-HBV activity with potency against HBsAg and HBeAg secretion by 59.7% and 34.7% at 50μg/mL .

HY-P4044

HBV Seq2 aa:28-39	HBV	Infection
HBV Seq2 aa:28-39 is a HBsAg peptide, which binds to major histocompatibility complex (MHC) class I molecules .

HY-P99703

Libivirumab 17.1.41	HBV	Infection
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC₅₀s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .

HY-109197

Vonafexor 1 Publications Verification EYP001	FXR HBV	Infection
Vonafexor (EYP001) is an orally active, non-steroidal and selective FXR agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research .

HY-161327

HBV-IN-44	HBV	Infection
HBV-IN-44 (Compound (S)-2a) is a HBV inhibitor with a IC₅₀ value of 23 nM for HbsAg. HBV-IN-44 is less toxic to the neurite growth of HT22 cells and DRG neurons in vitro .

HY-117650A

RG7834 5 Publications Verification RO 7020322	HBV	Infection
RG7834 (RO 7020322) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC₅₀s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells .

HY-148201

Oleana-2,12-dien-28-oic acid	HBV	Infection
Oleana-2,12-dien-28-oic acid is an HBV-DNA inhibitor, *HBsAg* and HBeAg inhibitor. Oleana-2,12-dien-28-oic acid can be used in hepatitis B virus infection disease research .

HY-145052

HBV-IN-9	HBV	Infection
HBV-IN-9 is a potent *HBsAg* (HBV Surface antigen) inhibitor (IC₅₀=10 nM) and HBV DNA production inhibitor (IC₅₀=0.15 nM in HepG2.2.15 cells) . From patent WO2018001952A1, example 20.

HY-P99693

Lenvervimab GC1102	HBV	Infection
Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection .

HY-N0854

Alisol F	HBV	Infection
Alisol F is a triterpene isolated from Alisma orinentale, has immunosuppressive and anti-virus functions. Alisol F exhibits inhibitory activity in vitro on hepatitis B virus (HBV) surface antigen (HBsAg) secretion of the HepG2.2.15 cell line with an IC₅₀ of 0.6 μM .

HY-134790

GST-HG131	HBV	Infection
GST-HG131 is a specific inbihitor of hepatitis B virus (HBV) surface antigen, belongs to dihydrobenzopyridooxazepine (DBP) series. GST-HG131 exhibits excellent and specific HBV antigens inhibition with EC₅₀ of 28.2 nM (HBsAg) and 16.0 nM (HBeAg), respectively, but also it is safety for animal .

HY-145713

GS-8873 HBV-IN-19	HBV	Infection
GS-8873 is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC₅₀ of 4 nM. GS-8873 exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 causes neurofunctional deficits in rats and cynomolgus monkeys .

HY-107315

Alisol F 24-acetate	HBV Apoptosis	Infection Cancer
Alisol F 24-acetate is a triterpene compound that can be isolated from the rhizomes of Alisma orientalis. Alisol F 24-acetate inhibits the secretion of HBV surface antigen *HBsAg* and HBeAg with IC₅₀ values of 7.7 µM and 5.1 µM. Alisol F 24-acetate has proapoptotic activity and can be used for cancer research .

HY-N11792

Pedunculosumoside F	Others	Others
Pedunculosumoside F is a homoflavonoid glucoside. Pedunculosumoside F can be isolated from Ophioglossum pedunculosum. Pedunculosumoside F has cytotoxicity against HepG2 22.15 cells with CC₅₀ value of 56.7 μM without anti-HBV activity. While its analogs block HBsAg secretion in HBV-infected HepG2 2.2.15 cells .

HY-N12102

Dihydrodehydrodiconiferyl alcohol 9-O-α-L-rhamnopyranoside	HBV	Infection
Dihydrodehydrodiconiferyl alcohol 9-O-α-L-rhamnopyranoside (compound 1) is a lignan with anti-HBC activity. Dihydrodehydrodiconiferyl alcohol 9-O-α-L-rhamnopyranoside targets HBV surface antigen with IC₅₀s of 0.58 mM (HBsAg) and >2.4 mM (HBeAg). Dihydrodehydrodiconiferyl alcohol 9-O-α-L-rhamnopyranoside can be isolated from star anise .

HY-N12105

Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside	HBV	Infection
Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside is an anti-hepatitis B virus (anti-HBV) agent. Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside inhibits HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) secretion on Hep G2.2.15 cell line, with IC₅₀ values of 1.67 and >2.15 mM, respectively .

HY-145713A

GS-8873 TFA HBV-IN-19 TFA	HBV	Infection
GS-8873 TFA is the TFA salt form of GS-8873 (HY-145713). GS-8873 TFA is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC₅₀ of 4 nM. GS-8873 TFA exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 TFA causes neurofunctional deficits in rats and cynomolgus monkeys .

HY-N8168

LPRP-Et-97543	HBV	Infection
LPRP-Et-97543 is a potent anti-HBV agent. LPRP-Et-97543 reduces Core, S, and preS but not X promoter activities. LPRP-Et-97543 can be used for acute and chronic HBV infections research .

HY-163124

HBV-IN-43	HBV	Infection
HBV-IN-43 (compound 5832) is a potent inhibitor of HBV .

Cat. No.	Product Name	Target	Research Area

HY-P5332

*Aβ1-14-εK-HBsAg3 Th* UB311 immunogen II	Peptides	Others
Aβ1-14-εK-HBsAg3 Th (UB311 immunogen II) is a biological active peptide. (one of UB-311's Aβ1–14–targeting peptides (B-cell epitope))

HY-P4043

Hepatitis b virus pre-s region (120-145)	HBV	Infection Inflammation/Immunology
Hepatitis b virus pre-s region (120-145) is a preS2 peptide that inhibits the binding of single-chain Fv fragment (scFv) or IgG to r-HBsAg .

HY-P4045

HBV Seq2 aa:208-216	HBV	Infection
HBV Seq2 aa:208-216, a HBsAg derived CD8 epitope peptide, is studied as part of Large envelope protein from Hepatitis B virus .

HY-P4044

HBV Seq2 aa:28-39	HBV	Infection
HBV Seq2 aa:28-39 is a HBsAg peptide, which binds to major histocompatibility complex (MHC) class I molecules .

Cat. No.	Product Name	Target	Research Area

HY-P99703

Libivirumab 17.1.41	HBV	Infection
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC₅₀s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .

HY-P990428

*Anti-HBsAg* Antibody (OST 577)**	Inhibitory Antibodies	Inflammation/Immunology

HY-P99541

Tuvirumab anti-hepatitis B; OST 577; SDZ-OST 577	HBV	Infection
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .

HY-P99693

Lenvervimab GC1102	HBV	Infection
Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection .

Species:	Virus (2)
Tag:	His (2)
Source:	E. coli Cell-free (1) P. pastoris (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P702356

	Large envelope Protein, HBV-D (Cell-Free, His) Large envelope protein; L glycoprotein; L-HBsAg; LHB; Large S protein; Large surface protein; Major surface antigen	Virus	E. coli Cell-free
	The large envelope protein has two conformations: “external” (Le-HBsAg) and “internal” (Li-HBsAg). In its external state, it mediates viral attachment, initiates infection, determines species specificity, and promotes viral particle internalization via caveolin-mediated endocytosis. Large envelope Protein, HBV-D (Cell-Free, His) is the recombinant Virus-derived Large envelope protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of Large envelope Protein, HBV-D (Cell-Free, His) is 388 a.a., with molecular weight of Monomer:40 kDa Dimer:80 kDa.

HY-P702559

	Large envelope Protein, HBV-C (P.pastoris, 180a.a, His) S; Large envelope protein; L glycoprotein; L-HBsAg; LHB; Large S protein; Large surface protein; Major surface antigen	Virus	P. pastoris
	The large envelope protein is crucial in its two conformations, "outside" (Le-HBsAg) and "inside" (Li-HBsAg). Externally, it binds the virus to cellular receptors, initiates infection, determines species specificity, and promotes viral particle internalization via caveolin-mediated endocytosis. Large envelope Protein, HBV-C (P.pastoris, 180a.a, His) is the recombinant Virus-derived Large envelope protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of Large envelope Protein, HBV-C (P.pastoris, 180a.a, His) is 180 a.a., with molecular weight of 20.9 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81076

	HBsAg Antibody (YA913) L glycoprotein; L-HBsAg; LHB; Large S protein; Large surface protein; Major surface antigen; S; HBsAg_HBVC5.	ELISA
	HBsAg Antibody (YA913) is an unconjugated, approximately 44 kDa, mouse-derived, anti-HBsAg (YA913) monoclonal antibody. HBsAg Antibody (YA913) can be used for: ELISA, expriments without labeling.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

HBsAg

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Antibodies

Natural
Products